2026-06-09 | Severe Hyperventilation Apnea Spells in Pitt Hopkins Syndrome and Beyond: A Remarkable Response to IV Diamox in the ICU (P6-8.011)
To report a case of recurrent hyperventilation apnea spells in an adolescent female with TCF4+ Pitt Hopkins Syndrome, focusing on the evolving insights into its pathophysiology and the established and investigational treatment strategies.
Open article ↗
2026-04-18 | Increasing MeCP2 protein in Pitt-Hopkins syndrome model (Tcf4+/-) mice does not affect abnormal myelination but induces the generation of astrocytes.
Pitt-Hopkins syndrome (PTHS) is a rare neurodevelopmental disorder that results from loss-of-function (LOF) mutations in the Transcription Factor 4 (TCF4) gene. PTHS closely resembles Rett syndrome (RTT), another neurodevelopmental disorder caused by mutations in the gene encoding Methyl CpG Binding Protein 2 (MECP2). We have recently shown that increasing MeCP2 levels, either genetically or via a viral vector approach, normalizes reciprocal behavioral phenotypes observed in Tcf4+/- and MECP2-overexpressing animals; in the current manuscript, we show that behavioral rescue also extends to a contextual fear learning task. Tcf4 heterozygous and knock-in mouse lines exhibit consistent myelination abnormalities, with an arrest of oligodendrocytes (OLs) at an immature stage. To address the hypothesis that correction of myelination defects is the potential mechanism underlying the behavioral rescue induced by MeCP2 increases in Tcf4+/- animals, we performed RNA-sequencing and protein expression studies. These experiments revealed that increasing MeCP2 does not dramatically affect the transcriptional profile induced by heterozygosity at Tcf4, as well as vice-versa, and subsequent molecular experiments suggest that OL gene expression and molecular phenotypes in Tcf4+/- animals are unchanged in the presence of an MECP2 transgene. However, we also find increased levels of Olig2 and Gfap co-expressing cells in Tcf4+/- mice in the presence of the MECP2 transgene, as well as the presence of cells with astrocytic morphology in the brains of these animals, suggesting a potential interplay of MeCP2 and TCF4 in astrocyte development.
Open article ↗
2026-02-12 | Pitt–Hopkins Syndrome: A Comprehensive Review for Healthcare and Nursing Practice
Pitt–Hopkins syndrome (PTHS) is a rare genetic neurodevelopmental disorder characterized by severe intellectual disability, distinctive facial dysmorphism, abnormal breathing patterns, epilepsy, and gastrointestinal dysfunction. The condition is caused by pathogenic variants in the TCF4 gene located on chromosome 18q21.2. Due to its rarity and phenotypic overlap with other neurodevelopmental disorders, Pitt–Hopkins syndrome is frequently underdiagnosed. Early identification and multidisciplinary intervention are essential to optimize developmental outcomes and improve quality of life. This article presents a plagiarism-safe, language-polished review of Pitt–Hopkins syndrome, focusing on etiology, clinical manifestations, diagnosis, management, and nursing implications relevant to healthcare professionals.
Open article ↗
2026-01-09 | Juvenile reinstatement of TCF4 in Pitt-Hopkins syndrome model mice reveals a critical window for genetic intervention.
Pitt-Hopkins syndrome (PTHS) is a neurodevelopmental disorder caused by haploinsufficiency of TCF4 which encodes transcription factor 4. As PTHS therapeutics advance toward clinical trials, identifying the optimal timing for treatment is crucial. Our previous research demonstrated that restoring TCF4 during embryonic or neonatal stages, corresponding to prenatal or neonatal periods in humans, improved phenotypes in a PTHS mouse model (Kim et al., 2022). However, PTHS diagnosis generally occurs much later, when infants fail to reach developmental milestones and undergo genetic testing. This raises an essential question: can genetic therapeutics initiated at more clinically relevant time points retain effectiveness? Here, we examined whether reinstating TCF4 in juvenile PTHS model mice could reverse behavioral phenotypes, simulating a gene therapy. Our findings indicate that this delayed intervention largely fails to correct most phenotypes, except for a measure of cognitive function. These results reveal phenotype-specific plasticity and underscore a narrow, early critical window for effective treatment in PTHS. Our study also identifies the hippocampus as a potential target for PTHS therapeutics and suggests that while some cognitive functions may still retain therapeutic plasticity, reversing most core PTHS symptoms may require intervention during the very early postnatal, or potentially prenatal periods, in humans.
Open article ↗
2026-01-08 | The E-Protein Daughterless Regulates Olfactory Learning of Adult Drosophila melanogaster.
Daughterless (Da), the Drosophila melanogaster homolog of mammalian E-protein transcription factor 4 (TCF4), is well studied in fruit fly embryonic development but its functions in adult nervous system are poorly understood. Mutations in human TCF4 gene lead to intellectual disabilities such as Pitt-Hopkins syndrome and TCF4 has also been linked to schizophrenia. Here, to explore the roles of Da in the Drosophila mature brain, we map Da DNA binding sites and study the transcriptomics of the brains where Da function is inhibited by pan-neuronal Extramacrohaete (Emc) overexpression, in both male and female Drosophila Our transcriptome analyses reveal that in the adult brain Da regulates the expression of genes involved in behavior, memory, synaptic signaling, protein translation, and metabolic processes. Moreover, combining the RNA sequencing data with Da ChIP sequencing results indicates that genes associated with neuronal projection guidance, metabolism, and translation are direct targets of Da. In addition, we validate the involvement of Da in memory formation. Overall, our results provide valuable information about the functions of Da in the adult brain and aid in better understanding the mechanisms of TCF4-related disorders.
Open article ↗
